Quote
148.81
-0.71 (-0.47%)
We have scored 106 news catalysts on MRK (MRK) over the past 12 months. Coverage across the window leans positive (average ticker sentiment +0.34). Most of the impact sits in sector healthcare and forward growth expectations.
Market cap
—
P/E
—
EPS
—
Beta
—
52W range
—
Day range
147.11–150.25
Open
148.97
Prev close
149.52
Volume
3.4M
Avg volume
—
Dividend
—
IPO
—
No scored news tagged MRK or its network in the window yet.
Show more MRK articles →Analysts publish price targets on MRK, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
24 analyst price targets from $105 to $180
as of 2026-09-11
The market is within 4% of the median target — broadly agreeing with the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about MRK — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of MRK, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for MRK: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The price sits at the 25th percentile of 24 published models, endorsing the near-consensus around $150 but explicitly declining to pay for the bull case of $170-$180 or accept the bear case of $105-$116.
What the disagreement turns on
Does the mRNA cancer vaccine expand Keytruda's effective patent life and total addressable market enough to justify the 12.2% revenue growth the price requires, and the available data cannot settle this because clinical trial outcomes are not a wired observable.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $145 on 2026-09-11 — 53 days ago.
